GE Healthcare launches MR contrast agent in Korea
GE Healthcare Korea recently announced the launch of Clariscan (gadoteric acid), a new macrocyclic MRI contrast agent, in Korea. Clariscan is a gadolinium-based contrast agent (GBCA) designed to support effective visualization of abnormalities in the brain, spine and associated tissues. As a macrocyclic and ionic GBCA, Clariscan is known to be a gold-standard detection tool in MR imaging, offering improved contrast between normal and pathological tissue to enable rapid detection of abnormalities. Clariscan is the latest in a line of products and services, including MRI, X-ray/CT and ultrasound modalities provided by GE Healthcare to the radiology profession for over 30 years and it is available at a range of doses in vials and pre-filled syringes. Clariscan will be added to the family of GE contrast media and imaging products alongside its existing linear agent for MRI, Omniscan, which has been used in routine diagnostic practice for over 25 years with over 80 million administrations.